Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Our Medicine
  • NASH
    • Overview
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
    • Email Alerts
  • Careers
    • Join the team
    • Core Values
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs
  • Email Alerts

Madrigal press releases are available below. Search them by keyword or browse by date.

January 3, 2025
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal’s ambitious research programs led to the first FDA-approved treatment in NASH.

Learn More
Madrigal Pharmaceuticals. Logo

Madrigal Pharmaceuticals

200 Barr Harbor Drive,
Suite 200

West Conshohocken,
Pennsylvania 19428

  • About Us
  • Our Programs
  • NASH
  • Investors & Media
  • Careers
  • Contact
Madrigal Pharmaceuticals
  • Terms of Use
  • Privacy
  • Cookies
  • ETHICS and COMPLIANCE
  • TRANSPARENCY
©2025 Madrigal Pharmaceuticals. All rights reserved.